Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1985 1
2006 1
2013 1
2017 1
2021 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Ruperto N, et al. Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9. Lancet. 2021. PMID: 34767764 Clinical Trial.
Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2023 Sep;75(9):1668-1677. doi: 10.1002/art.42512. Epub 2023 Jul 19. Arthritis Rheumatol. 2023. PMID: 36996276
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA, Yang Q, Gutierrez-Alamillo L, Pak K, Flegel WA, Mammen AL, Rider LG, Casciola-Rosen LA; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2024 Apr;76(4):631-637. doi: 10.1002/art.42768. Epub 2024 Jan 30. Arthritis Rheumatol. 2024. PMID: 38059274
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.
Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, Miller FW, Lundberg IE, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI226-SI234. doi: 10.1093/rheumatology/keac428. Rheumatology (Oxford). 2023. PMID: 35961028 Free PMC article.
Endophthalmitis after penetrating keratoplasty.
Guss RB, Koenig S, De La Pena W, Marx M, Kaufman HE. Guss RB, et al. Among authors: de la pena w. Am J Ophthalmol. 1983 May;95(5):651-8. doi: 10.1016/0002-9394(83)90385-9. Am J Ophthalmol. 1983. PMID: 6342401
Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.
Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group. Kishi T, et al. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113. Arthritis Care Res (Hoboken). 2017. PMID: 28129483 Free PMC article.
12 results